Latest publications

Early and long-term effects of dupilumab treatment on circulating T-cell functions in moderate-to-severe atopic dermatitis patients. Bakker DS, Van der Wal MM, Heeb LEM, Giovannone B, Asamoah M, Delemarre EM et al. J Invest Dermatol 2021 Feb 18

Development and Validation of Nomograms to Predict Local, Regional, and Distant Recurrence in Patients With Thin (T1) Melanomas. El Sharouni MA, Ahmed T, Varey AHR, Elias SG, Witkamp AJ, Sigurdsson V et al. J Clin Oncol 2021 Feb 18:JCO2002446

European Task Force on Atopic Dermatitis (ETFAD): position on vaccination of adult patients with atopic dermatitis against COVID-19 (SARS-CoV-2) being treated with systemic medication and biologics. Thyssen JP, Vestergaard C, Barbarot S, De Bruin-Weller MS, Bieber T, Taieb A et al. J Eur Acad Dermatol Venereol 2021 Feb 15

Laboratory safety of dupilumab for up to 3 years in adults with moderate-to-severe atopic dermatitis: results from an open-label extension study. Beck LA, Thaçi D, Deleuran M, De Bruin-Weller M, Chen Z, Khokhar FA et al. J Dermatolog Treat 2021 Feb 08:1-9

Identification and Purification of Novel Low-Molecular-Weight Lupine Allergens as Components for Personalized Diagnostics. Jappe U, Karstedt A, Warneke D, Hellmig S, Böttger M, Riffelmann FW et al. Nutrients 2021 Jan 28; 13(2)

Accidental food-allergic reactions are associated with higher costs and more sick leave but not with quality of life. Versluis A, Knulst AC, Michelsen-Huisman AD, Houben GF, Blom WM, Le TM et al. Clin Exp Allergy 2021 Feb 01

Treat-to-Target in Atopic Dermatitis: An International Consensus on a Set of Core Decision Points for Systemic Therapies. De Bruin-Weller M, Biedermann T, Bissonnette R, Deleuran M, Foley P, Girolomoni G et al. Acta Derm Venereol 2021 Feb 17; 101(2):adv00402

Conjunctivitis in Dupilumab Clinical Trials for Adolescents with Atopic Dermatitis or Asthma. Bansal A, Simpson EL, Paller AS, Siegfried EC, Blauvelt A, De Bruin-Weller M et al. Am J Clin Dermatol 2021 Jan; 22(1):101-115

Disease burden and treatment history among adults with atopic dermatitis receiving systemic therapy: baseline characteristics of participants on the EUROSTAD prospective observational study. Bruin-Weller M, Pink AE, Patrizi A, Gimenez-Arnau AM, Agner T, Roquet-Gravy PP et al. J Dermatolog Treat 2021 Mar; 32(2):164-173

Allergen labelling: Current practice and improvement from a communication perspective. Blom WM, Van Dijk LM, Michelsen-Huisman A, Houben GF, Knulst AC, Linders YFM et al. Clin Exp Allergy 2021 Jan 13

Subtyping Cutaneous Melanoma Matters. El Sharouni MA, Van Diest PJ, Witkamp AJ, Sigurdsson V, Van Gils CH et al. JNCI Cancer Spectr 2020 Dec; 4(6):pkaa097

Association of Histologic Regression With a Favorable Outcome in Patients With Stage 1 and Stage 2 Cutaneous Melanoma. El Sharouni MA, Aivazian K, Witkamp AJ, Sigurdsson V, Van Gils CH, Scolyer RA et al. JAMA Dermatol 2021 Feb 01; 157(2):166-173

Safety and effectiveness of omalizumab for the treatment of chronic urticaria in pediatric patients. Dekkers C, Alizadeh Aghdam M, De Graaf M, Knulst AC, Meijer Y, Van den Reek JMPA et al. Pediatr Allergy Immunol 2020 Dec 11

EASI p-EASI: Predicting disease severity in atopic dermatitis patients treated with dupilumab using a combination of serum biomarkers. Bakker DS, Ariens LFM, Giovannone B, Hijnen D, Delemarre EM, Knol E et al. Allergy 2020 12; 75(12):3287-3289

IgE-binding to vicilin-like antimicrobial peptides is associated with systemic reactions to macadamia nut. Ehlers AM, Rohwer S, Otten HG, Brix B, Le TM, Suer W et al. Clin Transl Allergy 2020 Dec 02; 10(1):55